Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 119 |
| Active Pipeline (Recruiting Now) | 38 (16) |
| Completed vs Stopped Early | 47 / 34 (28.6%) |
| Median Closed Actual Enrollment | 99 participants |
| Physical Hospital Site Disclosure | 82.7% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 6 (5 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hospital Universitario 12 de Octubre | Madrid | 19 |
| Hospital Universitario Ramon y Cajal | Madrid | 17 |
| Hospital de La Santa Creu I Sant Pau | Barcelona | 17 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06804811 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | Phase III | RECRUITING |
| NCT07023627 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase II | RECRUITING |
| NCT07623200 | A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia | Phase III | RECRUITING |
| NCT05090891 | To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | Phase II | RECRUITING |
| NCT06585774 | A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | Phase III | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Incyte Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.